**1. Financial Highlights:** Q1 FY26 saw revenue at Rs. 97.58 Cr, down from Rs. 122.99 Cr year-on-year, impacted by a high-margin business disruption.

The company reported a Q1 PAT loss of Rs. 14.22 Cr and an EBITDA loss of Rs. 10.08 Cr.

Despite this, the balance sheet remains strong, with a Total Debt to Equity of 0.21 as of FY25. **2. Strategic Initiatives & Growth Drivers:** Management is focusing on cost rationalization, optimizing field force productivity, and enhanced working capital management.

Key growth drivers include selective investments in high-margin brands and a robust R&D pipeline aimed at differentiated products in critical therapeutic categories.

The company aspires for leadership in the Hospital Business and plans expansion into new RoW markets, targeting a 35% CAGR over the next three years. **3. Business Developments:** The API business showed strong recovery, growing 77% year-on-year and 52% quarter-on-quarter.

The Institution business also grew in Q1, with the Pharma business achieving 19% year-on-year growth.

The formulations segment grew 35% quarter-on-quarter, and Hospital and Trade businesses expanded significantly.

Export orders are anticipated to be achieved in Q2 after initial delays. **4. Market Position & Competitive Advantage:** Themis Medicare aims to be a leader in India's Hospital Business, particularly in Critical Care and Anesthesia.

Its vertically integrated state-of-the-art manufacturing facilities (Formulations, Synthetic & Biotech APIs) hold EU GMP approvals.

The company leverages high entry barriers in the hospital segment due to the need for a large product portfolio and strong key account relationships. **5. Investor Implications:** While Q1 FY26 profitability was challenged by market imitation issues, the strategic focus on high-growth segments like API and Hospital Business, coupled with R&D investments and a strong balance sheet, indicates positive growth potential.

Management anticipates a significant bounce back in subsequent quarters, suggesting that the current period's disruption is a short-term risk to monitor against long-term strategic execution.